Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 14/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9370134 | 0.89 | RIPK1 (1.00) | RIPK1ALDH1A1L3MBTL1 | |
| SCHEMBL9378782 | 0.88 | RIPK1 (0.80) | RIPK1L3MBTL1NPSR1KMT2ASMN1; SMN2 | |
| SCHEMBL9378120 | 0.87 | RIPK1 (0.88) | RIPK1ALDH1A1L3MBTL1 | |
| SCHEMBL9378058 | 0.87 | RIPK1 (0.74) | RIPK1ALDH1A1L3MBTL1 | |
| SCHEMBL9377762 | 0.87 | RIPK1 (0.74) | RIPK1ALDH1A1NPSR1KMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL20138382 | 0.82 | RIPK1 (0.86) | RIPK1ALDH1A1L3MBTL1 | |
| SCHEMBL9378720 | 0.82 | RIPK1 (0.70) | RIPK1ALDH1A1L3MBTL1NPSR1KMT2A | |
| SCHEMBL18255206 | 0.81 | RIPK1 (0.81) | RIPK1ALDH1A1KMT2A | |
| SCHEMBL9377821 | 0.80 | RIPK1 (0.70) | RIPK1ALDH1A1NPSR1KMT2ASMN1; SMN2 | |
| SCHEMBL2481688 | 0.79 | RIPK1 (0.66) | RIPK1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0295695-B1 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS (JP) | 1994-06-08 | — | — | EP | claimed |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-01 | — | — | US | disclosed |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| CN-112370452-A | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-10899716-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-01-26 | — | — | US | disclosed |
| CN-107624111-B | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-11-03 | — | — | CN | disclosed |
| US-20200165205-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| EP-3298002-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016185423-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-11-24 | — | — | WO | disclosed |
| EP-0295695-B1 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-4990529-A | Nervous system disorder | MITSUI TOATSU CHEMICALS (JP) | 1991-02-05 | — | — | US | disclosed |
| US-4839376-A | Pyrazoline derivatives for treating cerebrovascular diseases | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-06-13 | — | — | US | disclosed |
| EP-0295695-A2 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1988-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | RIPK1 414/4885ALDH1A1 1542/4885L3MBTL1 1895/4885 |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | MAP3K19, MAP3K20, MAP3K1 | RIPK1 405/4885ALDH1A1 1576/4885L3MBTL1 2142/4885 |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | RIPK1 405/4885ALDH1A1 1576/4885L3MBTL1 2142/4885 |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | RIPK1 405/4885ALDH1A1 1576/4885L3MBTL1 2142/4885 |
| US-10899716-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | RIPK1 405/4885ALDH1A1 1576/4885L3MBTL1 2142/4885 |
| US-20200165205-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | RIPK1 405/4885ALDH1A1 1576/4885L3MBTL1 2142/4885 |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | RIPK1 414/4885ALDH1A1 1542/4885L3MBTL1 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.